- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
ALPS Medical Breakthroughs ETF(SBIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SBIO
11/20/2026: SBIO (1-star) is currently NOT-A-BUY. Pass it for now.
The ALPS Medical Breakthroughs ETF (SBIO) provides targeted exposure to small- and mid-cap biotechnology companies with drugs in Phase II or Phase III clinical trials. Its main strengths lie in its specialized index methodology that filters out early research risk while avoiding mega-cap pharma dilution, all at a reasonable 0.50% expense ratio. It functions primarily as a tactical satellite allocation to capture clinical milestones and sector M&A upside. Key risks include high volatility, binary clinical trial outcomes, and sensitivity to financing conditions. It suits aggressive growth investors comfortable with sector-specific concentration and drawdown risks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Suits growth-oriented mandates targeting high-potential scientific breakthroughs and clinical expansions. |
| Momentum investor | Strong fit while signal remains positive | Appeals to momentum strategies during periods when biotech sentiment and clinical trial catalysts trend upward. |
| Value investor | Weak fit | Pre-revenue clinical-stage firms frequently lack traditional earnings or fundamental value metrics. |
| Dividend/Income investor | Weak fit | Portfolio holdings reinvest cash flows into research and development rather than distributing dividends. |
| Low-risk investor | Weak fit | High volatility and binary clinical trial risks conflict with capital-preservation goals. |
Investor Profile
Ideal Investor Profile
Growth-oriented or tactical sector investors seeking high-beta exposure to mid-stage drug development catalysts with a high tolerance for volatility.
Suitability
Best utilized as a tactical satellite allocation for experienced investors rather than a core long-term portfolio holding.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Clinical-stage biotechnology stocks experience severe price swings based on trial updates. |
| Market risk | High | Broader equity market corrections can heavily compress valuations across speculative biotech sectors. |
| Concentration | Medium / high | The fund is concentrated entirely within the clinical-stage biotechnology industry segment. |
| Tracking/expense | Low | Passive index replication introduces minimal tracking error relative to its targeted benchmark. |
| Liquidity | Medium / high | Lower average daily volume compared to broad market funds can increase execution costs. |
| Business/sector quality | High | Many constituent companies generate little to no revenue while relying heavily on external financing. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
SBIO exhibits high historical volatility due to its exclusive focus on clinical-stage biotechnology firms whose valuations swing sharply on trial outcomes.
Market Risk
Underlying assets face acute risks including regulatory rejection, clinical trial failure, lack of commercial revenue, and sensitivity to risk-off market sentiment.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Small- and Mid-Cap Clinical-Stage Biotechnology Equities | Provides targeted exposure to clinical-stage biotech firms advancing innovative drug pipelines through Phase II and Phase III trials. | |
| Cash/collateral | Cash and Cash Equivalents | Maintains minor liquidity buffers for daily administrative operations and dividend or corporate action flows. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 105.44% | Avg. Invested days 88 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

